The REACH Program comprised 2 global phase III trials (REACH and REACH-2) that identified AFP as a biomarker for treatment selection for CYRAMZA in advanced HCC1,2,4,5
The REACH‑2 trial was purposefully designed to evaluate AFP as a biomarker for treatment selection1,2
SELECT IMPORTANT SAFETY INFORMATION
- CYRAMZA can increase the risk of gastrointestinal perforation, a potentially fatal event. In 2137 patients with various cancers treated with CYRAMZA, the incidence of all Grade and Grade 3-5 gastrointestinal perforations ranged from <1-2%.
- Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation.